^
Association details:
| Biomarker: | MCM10 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer
Published date:
08/22/2018
Excerpt:
...Three independent breast cancer patient datasets with treatment details (chemotherapy with or without trastuzumab depending on the HER2 status) and response to treatment were included in the analysis. In GSE22226 (n = 124), patients who achieved pathological complete response (pCR) after neoadjuvant treatment had a significantly higher expression of MCM10 compared to those patients who did not achieve pCR after treatment (p = 0.037)...
Secondary therapy:
Chemotherapy
DOI:
10.3390/cancers10090282